The US Air Force seeks a partner to license and commercialize an endovascular variable aortic control (EVAC) catheter for resuscitative occlusion of arteries and control of blood flow during life-threatening hemorrhage
The 60th Medical Group at Travis Air Force Base has developed improved devices for hemostatic management of patients with life-threatening blood loss from an arterial wound or surgery. Current aortic occlusion devices successfully stem aortic blood loss but result in hypoxia below the occlusion device. These devices, by blocking blood flow and oxygen delivery, severely limit the amount of time that such resuscitative measures can be taken before other medical complications arise. The major improvement in the present endovascular variable aortic control (EVAC) device is that it occludes blood flow, but not entirely, with some control. Specifically, EVAC allows greater control in the level of aortic blood flow and pressure on either side of the occlusion barrier.
EVAC features either non-balloon or balloon-based occlusion capabilities in a multi-lumen catheter, which includes an external regulation device that allows medical staff to regulate blood flow and pressure by affecting the aperture of the window in the main channel of the device.
• Increases the amount of time a patient with severe blood loss has to reach definitive vascular repair
• Allows up to 15% blood flow within the occluded vessel while maintaining internal blood pressure
• External regulation of blood flow and pressure possible through a device affecting aperture of internal lumen
• Diverse potential applications including arteries and other vessels away from the heart
• US 2016/0206798, WO201611859, and unpublished patent applications are available for license
• Additional information available below